Moderna, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

Clinical trial results Company update Drug approval AI-generated analysis

πŸ“ˆ BioNTech achieved FY 2025 revenue growth of 4.3% to nearly $3.2 billion, demonstrating resilience despite the post-pandemic market shift.

πŸ’° BioNTech holds approximately €16.2 billion in cash and investments as of September 2026 with zero debt, providing exceptional financial flexibility.

πŸ“‰ Moderna experienced a significant 40% revenue decline to $1.9 billion in FY 2025 due to weakening COVID-19 vaccine sales.

πŸ”„ Moderna demonstrated improving momentum in Q3 2026 with a 29% revenue surge to $1.3 billion and a return to profitability with $162 million net income.

🀝 BioNTech is leveraging its mRNA expertise through strategic partnerships with major pharmaceutical firms like Bristol Myers Squibb and Roche for oncology treatments.

🧬 Moderna is advancing a promising personalized cancer vaccine in partnership with Merck, targeting a potential commercial launch in 2027.

βš–οΈ The article identifies BioNTech as the preferred buy for 2027 due to its stronger balance sheet and lower financial risk compared to Moderna.

πŸ₯ Both companies face intense competition and clinical risks in their oncology pipelines, which could impact future revenue generation timelines.

Bullish Signals
  • Moderna demonstrated a strong recovery in Q3 2026 with revenue surging 29% to $1.3 billion and achieving net income of $162 million after a period of losses.
  • Moderna raised its full-year revenue growth outlook to a range of 15%–25%, signaling improved market momentum and investor confidence in its pipeline.
  • The company holds approximately $8 billion in cash and investments, providing substantial resources to fund its oncology research and development programs.
Risk Factors
  • Moderna reported a severe 40% year-over-year revenue decline to $1.9 billion in FY 2025 as COVID-19 vaccine sales weakened significantly.
  • Moderna's cash position relies partly on new convertible debt financing, introducing refinancing risk and potential dilution concerns for shareholders.
Full Analysis
Biotechnology leaders BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable growth in oncology and other therapeutic areas. BioNTech reported FY 2025 revenue of nearly $3.2 billion, a 4.3% increase, but posted a net loss of approximately $1.3 billion driven by heavy investment in its oncology pipeline. The company holds substantial cash reserves of roughly €16.2 billion as of September 2026 and maintains zero debt, positioning it for continued research without immediate external financing needs. Moderna generated $1.9 billion in revenue for FY 2025, representing a sharp 40% year-over-year decline due to weakening vaccine sales, alongside a net loss of $2.8 billion. However, the company showed signs of recovery in Q3 2026 with a 29% revenue increase to $1.3 billion and a return to net income of $162 million. Moderna holds about $8 billion in cash and investments, supported by convertible debt financing, while advancing its personalized cancer vaccine developed in partnership with Merck. The article concludes that BioNTech is the preferred investment choice for 2027 due to its superior financial resilience, specifically citing its positive cash flow, zero debt load, and massive cash hoard compared to Moderna's cash consumption and premium valuation. While both companies face clinical risks and competition in cancer treatments, BioNTech's expanding oncology pipeline combined with its fiscal security offers a more attractive balance of downside protection and long-term upside potential for investors.